G.GroupP
Less hunger
Verified review - view original Tolerable, no nausea or headaches
Patient out-of-pocket costs of USD 200 to USD 500 monthly drive the 68% GLP-1 drug discontinuation rate in real-world adherence studies within the first 12 months of therapy
While FDA does not limit compounding to drug shortages and we believe there are paths to continue offering access to certain compounded GLP-1s after the shortage ends, we cannot guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all, due to a variety of factors outside our control, including supply chain, intellectual property, regulatory and resource allocation matters.) On October 2, 2024, this risk materialized when FDA announced on its website that Lilly had resolved the tirzepatide shortage, meaning that companies making and distributing compounded copies needed to stop in their tracks, regardless of ongoing patient care
LCarnitine Discover how LCarnitine fuels brain energy, sharpens focus, and protects dopamine pathways to lift mood
